⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ammonia Solution, Strong SCHEMBL10787567 | 0.95 | — | — | |
| SCHEMBL9660945 | 0.78 | — | — | |
| Urea SCHEMBL27464354 | 0.78 | — | — | |
| SCHEMBL10139 | 0.78 | — | — | |
| SCHEMBL28084851 | 0.78 | — | — | |
| SCHEMBL3691779 | 0.76 | LDHA (0.43) | — | |
| SCHEMBL3691782 | 0.76 | LDHA (0.43) | — | |
| Urea SCHEMBL4814143 | 0.74 | — | — | |
| Urea SCHEMBL11569843 | 0.74 | — | — | |
| Hydrochloric Acid SCHEMBL4395995 | 0.74 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 228 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0749429-B1 | 3,5-DISUBSTITUTED AND 3,5,6-TRISUBSTITUTED 2-ISOXAZOLINES AND ISOXAZOLES, PROCESS FOR PREPARING THE SAME AND THEIR USE AS MEDICAMENTS | HOECHST AG (DE) | 1999-06-30 | — | — | EP | claimed |
| EP-0638074-B1 | ISOXAZOLE CARBOXYLIC ACID AMIDES, PROCESS FOR PRODUCING THEM AND THEIR USE | BASF AG (DE) | 1999-03-31 | — | — | EP | claimed |
| US-5814627-A | ANTIINFLAMMATORY AGENTS, ASTHMA; RHEUMATIC AND AUTOIMMUNE DISEASES; INHIBITORS OF LEUKOTRIENES, CYTOKINES, E.G. INTERLEUKINS, OXYGEN RADICALS AND PROTEASES | HOECHST AKTIENEGESELLSCHAFT (DE) | 1998-09-29 | — | — | US | claimed |
| EP-0490263-A1 | Alpha-oxoacetamide derivatives | SYNTEX (U.S.A.) INC. (US) | 1992-06-17 | — | — | EP | claimed |
| EP-0054872-B1 | 3,4-DI-SUBSTITUTED 1,2,5-OXADIAZOLE-2 OXIDES, METHOD FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | CASSELLA Aktiengesellschaft (DE) | 1984-10-31 | — | — | EP | claimed |
| US-20260035357-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCE INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12404262-B2 | Therapeutic compounds for HIV virus infection | GILEAD SCIENCES, INC. (US) | 2025-09-02 | — | — | US | disclosed |
| EP-4440701-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2024-10-09 | — | — | EP | disclosed |
| US-20230250248-A1 | CATALYST-FREE SURFACE FUNCTIONALIZATION AND POLYMER GRAFTING | ILLUMINA, INC. | 2023-08-10 | — | — | US | disclosed |
| US-20230212148-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. | 2023-07-06 | — | — | US | disclosed |
| WO-2023102523-A1 | THERAPEUTIC COMPOUNDS FOR HIV VIRUS INFECTION | GILEAD SCIENCES, INC. (US) | 2023-06-08 | — | — | WO | disclosed |
| US-11618808-B2 | Catalyst-free surface functionalization and polymer grafting | ILLUMINA, INC. (US) | 2023-04-04 | — | — | US | disclosed |
| US-4144345-A | Dihydroxybenzisoxazolin-3-yl-substituted-5-nitroimidazoles as antibacterials and antiprotozoals | MERCK & CO., INC. (US) | 1979-03-13 | — | — | US | disclosed |
| US-4144047-A | SOYBEANS | MONSANTO COMPANY (US) | 1979-03-13 | — | — | US | disclosed |
| US-4136180-A | HYPOLIPIDEMIC SUBSTITUTED STYRENESULFONYLUREAS | PFIZER INC. (US) | 1979-01-23 | — | — | US | disclosed |
| US-4129568-A | 2-[3-Aryl-2-isoxazolin-5-yl]benzoates | MONSANTO COMPANY (US) | 1978-12-12 | — | — | US | disclosed |
| US-4080340-A | Nitroimidazoles | MERCK & CO., INC. (US) | 1978-03-21 | — | — | US | disclosed |
| US-4062960-A | Hypolipidemic alkenesulfonamides | PFIZER INC. (US) | 1977-12-13 | — | — | US | disclosed |
| US-4010176-A | Isoxazole substituted nitroimidazoles | MERCK & CO., INC. (US) | 1977-03-01 | — | — | US | disclosed |
| US-3983107-A | ARTERIOSCLEROSIS | PFIZER INC. (US) | 1976-09-28 | — | — | US | disclosed |